Outlook Therapeutics’ (OTLK) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Outlook Therapeutics (NASDAQ:OTLK) in a report issued on Thursday, Benzinga reports. HC Wainwright currently has a $30.00 price target on the stock. HC Wainwright also issued estimates for Outlook Therapeutics’ FY2027 earnings at $1.17 EPS and FY2028 earnings at $3.14 EPS.

Outlook Therapeutics Stock Performance

NASDAQ OTLK traded up $0.12 on Thursday, hitting $7.80. 167,899 shares of the stock traded hands, compared to its average volume of 379,230. The business’s fifty day moving average is $7.67 and its two-hundred day moving average is $8.06. Outlook Therapeutics has a 12 month low of $4.00 and a 12 month high of $29.20. The firm has a market capitalization of $182.60 million, a price-to-earnings ratio of -0.69 and a beta of 0.71.

Outlook Therapeutics (NASDAQ:OTLK) last posted its quarterly earnings data on Wednesday, May 15th. The company reported ($1.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.67). Analysts expect that Outlook Therapeutics will post -4.08 EPS for the current fiscal year.

Institutional Investors Weigh In On Outlook Therapeutics

Large investors have recently added to or reduced their stakes in the business. AQR Capital Management LLC bought a new stake in Outlook Therapeutics during the second quarter valued at $75,000. Squarepoint Ops LLC purchased a new stake in Outlook Therapeutics during the second quarter valued at about $232,000. Susquehanna Fundamental Investments LLC purchased a new stake in Outlook Therapeutics during the second quarter valued at about $303,000. Great Point Partners LLC raised its position in Outlook Therapeutics by 15.0% during the second quarter. Great Point Partners LLC now owns 1,701,510 shares of the company’s stock valued at $12,557,000 after purchasing an additional 221,510 shares in the last quarter. Finally, LVW Advisors LLC purchased a new stake in Outlook Therapeutics during the second quarter valued at about $352,000. Institutional investors own 11.20% of the company’s stock.

About Outlook Therapeutics

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.